Emerging evidence of the impact of kidney disease on drug metabolism and transport

被引：209
作者：
Nolin, T. D. [4 ,5 ]
Naud, J. [1 ,2 ,3 ]
Leblond, F. A. [1 ,2 ]
Pichette, V. [1 ,2 ,3 ]
机构：
[1] Hop Maison Neuve Rosemont, Ctr Rech, Montreal, PQ H1T 2M4, Canada
[2] Hop Maison Neuve Rosemont, Serv Nephrol, Montreal, PQ H1T 2M4, Canada
[3] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada
[4] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME USA
[5] Maine Med Ctr, Dept Med, Div Nephrol & Transplantat, Portland, ME 04102 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷 / 06期
关键词：
D O I：
10.1038/clpt.2008.59
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Several lines of emerging evidence indicate that kidney disease differentially affects uptake and efflux transporters and metabolic enzymes in the liver and gastrointestinal (GI) tract, and uremic toxins have been implicated as the cause. In patients with kidney disease, even drugs that are eliminated by nonrenal transport and metabolism could lead to important unintended consequences if they are administered without dose adjustment for reduced renal function. This is particularly so in the case of drugs with narrow therapeutic windows and may translate into clinically significant variations in exposure and response.
引用
收藏
页码：898 / 903
页数：6
相关论文
共 38 条
[1]   BIOAVAILABILITY AND KINETICS OF CIBENZOLINE IN PATIENTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION [J].
ARONOFF, G ;
BRIER, M ;
MAYER, ML ;
BARBALAS, M ;
AOGAICHI, K ;
SLOAN, R ;
BRAZZELL, R ;
MASSARELLA, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (01) :38-44
[2]   PHARMACOKINETICS OF LOMEFLOXACIN IN RENALLY COMPROMISED PATIENTS [J].
BLUM, RA ;
SCHULTZ, RW ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (12) :2364-2368
[3]   Prevalence of chronic kidney disease in the United States [J].
Coresh, Josef ;
Selvin, Elizabeth ;
Stevens, Lesley A. ;
Manzi, Jane ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Levey, Andrew S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (17) :2038-2047
[4]   Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency [J].
Coulomb, F ;
Ducret, F ;
Laneury, JP ;
Fiorentini, F ;
Poggesi, I ;
Jannuzzo, MG ;
Fleishaker, JC ;
Houin, G ;
Duchêne, P .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (05) :482-487
[5]   Raloxifene pharmacokinetics in males with normal and impaired renal function [J].
Czock, D ;
Keller, F ;
Heringa, M ;
Rasche, FM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (04) :479-482
[6]   Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis [J].
De Martin, Sara ;
Orlando, Rocco ;
Bertoli, Massimo ;
Pegoraro, Paola ;
Palatini, Pietro .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) :597-606
[7]   Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease [J].
Dowling, TC ;
Briglia, AE ;
Fink, JC ;
Hanes, DS ;
Light, PD ;
Stackiewicz, L ;
Karyekar, CS ;
Eddington, ND ;
Weir, MR ;
Henrich, WL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) :427-434
[8]   Cytochrome P4502C9 activity in end-stage renal disease [J].
Dreisbach, AW ;
Japa, S ;
Gebrekal, AB ;
Mowry, SE ;
Lertora, JJL ;
Kamath, BL ;
Rettie, AE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) :475-477
[9]   Effects of uptake and efflux transporter inhibition on erythromycin breath test results [J].
Frassetto, L. A. ;
Poon, S. ;
Tsourounis, C. ;
Valera, C. ;
Benet, L. Z. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (06) :828-832
[10]   Single-dose pharmacokinetics of felbamate in patients with renal dysfunction [J].
Glue, P ;
Sulowicz, W ;
Colucci, R ;
Banfield, C ;
Pai, S ;
Lin, C ;
Affrime, MB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (01) :91-93
1234